Cure8 research brief
The study identifies a food-industry by-product (crayfish shells) as a source of peptides that reduced inflammation and improved barrier and antioxidant markers in cell and mouse colitis models—research that could inform future nutritional or therapeutic development for IBD.
Researchers studying IBD mechanisms, nutraceutical or functional-food developers, translational clinicians interested in preclinical anti-inflammatory agents, and patients curious about early-stage dietary compound research.
This is a preclinical laboratory study that used biochemical assays, intestinal epithelial cells (IEC-6) stimulated with LPS, and mice given dextran sulfate sodium (DSS) to model colitis.
The alkaline protease-derived hydrolysate (ACSP) showed radical-scavenging activity in vitro, improved antioxidant enzyme activity, lowered pro-inflammatory markers (iNOS, IL-1β, IL-6, TNF-α) while increasing IL-10 in cells, and reduced disease activity, colon injury, and inflammatory markers in DSS mice.
The article also includes peptidomic analysis identifying hundreds of peptide sequences in ACSP, framing these crayfish shell by-products as a potential sustainable source of bioactive peptides for intestinal-health applications.
This is preclinical work (cells and DSS mouse model). Results in animal models often do not translate directly to humans; the paper supports further investigation rather than clinical use.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China, award 32302019; award 32302019; Research Fund for Key R&D projects in Hubei Province, award 2022BBA0053
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This mouse study identifies a novel peptide that reduced DSS-induced colitis and points to mast cells and fibroblast–mast cell interactions as potential therapeutic targets. It also showed additive benefit when combined...
This study suggests a new, non‑live (“postbiotic”) approach—extracellular vesicles from pasteurized Akkermansia muciniphila—may reduce inflammation and improve barrier function in an experimental colitis model, which...
The study suggests a novel plant-derived nanoparticle approach reduced inflammation and repaired barrier function in a mouse model of colitis and changed the gut microbiome — a potential early-stage route for new IBD...
